Clarion vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI healthcare communication platform handling patient scheduling, billing, and prescriptions; backed by Accel and YC quadrupling revenue while serving a $5B health insurance provider.
About
Clarion is an AI healthcare communication platform that deploys intelligent voice and messaging agents to handle high-volume patient interactions for clinics and health systems — automating appointment scheduling, billing inquiries, prescription refill requests, and patient follow-up communications that currently consume significant front-office staff time. Founded in 2024 and backed by Accel, Y Combinator, and Sequoia Scout with $5.4-5.8 million raised, Clarion has quadrupled revenue in recent months while serving tens of thousands of patients monthly across virtual care companies, health systems, and a $5 billion health insurance provider.\n\nClarion's AI agents handle patient-initiated contacts across phone, SMS, and web channels — scheduling appointments without hold times, answering billing questions, processing routine prescription refill requests, and sending proactive outreach for appointment reminders and care gap closures. The agents integrate with EHR systems (Epic, athenahealth) and practice management systems to access patient records and schedule availability, enabling context-aware conversations that feel more like interacting with an informed staff member than a phone tree.\n\nIn 2025, Clarion competes in the healthcare AI communication and patient engagement market with Nuance (Microsoft Dragon Ambient and DAX), Relatient (patient scheduling and communication), and Klara (patient messaging platform) for healthcare front-office automation. The healthcare front office represents one of the most labor-intensive and patient-satisfaction-critical functions in a medical practice — phone hold times and scheduling difficulties are top complaints from patients. Accel and Sequoia Scout backing at the seed stage reflects conviction about the market size and Clarion's early commercial traction. The 2025 strategy focuses on growing within health systems and virtual care companies, deepening EHR integrations, and expanding the AI agent capabilities to handle more complex patient interaction types beyond routine scheduling.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.